# Drug Eluting Balloons Market

> Drug Eluting Balloons Market Research Report Information By Product (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon And Others), By Technology (Paccocath, FreePac, TransPax, EnduraCoat, Others), By End-user (Hospitals and Ambulatory Surgery Centers, Cath Labs And Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.5%
- **2024:** $ 0.66 Billion
- **2025:** $ 0.71 Billion
- **2035:** $ 1.46 Billion
- **Key Players:** Medtronic (US), Boston Scientific (US), B. Braun Melsungen AG (DE), Abbott Laboratories (US), Cordis Corporation (US), Cook Medical (US), Terumo Corporation (JP), Asahi Intecc Co., Ltd. (JP), Essen Medical (DE)

**Report ID:** MRFR/HC/20571-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/drug-eluting-balloons-market-22171

---

## Market Summary

## **Global Drug Eluting Balloons Market Overview**

Drug Eluting Balloons Market Size was valued at USD 0.61 Billion in 2023. The Drug Eluting Balloons Market industry is projected to grow from USD 0.66 Billion in 2024 to USD 1.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032). Increasing demand for cath labs and favorable reimbursement policies are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Drug Eluting Balloons Market Trends**

The increasing prevalence of coronary artery disease and diabetes is likely to drive market CAGR in the drug eluting balloon over the forecast period. Drug-eluting balloons are angioplasty balloons that play an important role in the treatment of coronary heart disease. The high prevalence of coronary artery disease is likely to increase demand for angioplasty and other therapies, hence driving market expansion. According to the World Health Organization (WHO), coronary heart disease kills approximately 3.8 million men and 4.4 million women each year.

Furthermore, the number of fatalities between the ages of 15 and 59 is estimated to reach 1332 million, with an additional 5825 million occurring after the age of 60.

Additionally, diabetes can damage blood vessels and neurons in the heart, which can lead to cardiovascular disease. As a result, the increasing prevalence of diabetes is likely to drive growth in the medication-eluting balloon market throughout the forecast period. For example, according to the World Health Organization's October 2018 report, diabetes causes approximately 1.6 million deaths worldwide. According to the Centers for Disease Control and Prevention, 537 million adults (20-79 years old) worldwide had diabetes in 2021, accounting for one in every ten people.

China has the world's biggest number of diabetics, with over 141 million individuals suffering from the condition. By 2045, China is expected to have over 174 million diabetics.

In addition, according to the Centers for Disease Control and Prevention, the highest prevalence of diagnosed diabetes in 2019 was among American Indians and Alaska Natives (14.5%), followed by non-Hispanic Blacks (12.1%), people of Hispanic origin (11.8%), non-Hispanic Asians (9.5%), and non-Hispanic Whites. According to the World Health Organization, 3.1 million persons aged 20 and up, or 10.8% of all adults in the United States with diabetes, began using insulin within a year of being diagnosed. Thus driving the Drug Eluting Balloons Market revenue.

## **Drug Eluting Balloons Market Segment Insights**

### **Global Drug Eluting Balloons Product Insights**

The Drug Eluting Balloons Market segmentation, based on Product, includes Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon and Others. In 2023, the Peripheral Drug Eluting Balloon category accounted for 72.64% of the global market, the biggest share. The American Heart Association's 2021 report addresses peripheral artery disease (PAD), which affects over 200 million people worldwide and has been associated with high mortality and morbidity. The aging of the global population is likely to result in an increase in PAD instances in the future.

According to the statistics, the number of PADs is increasing at a faster rate, which is driving market expansion.

**Figure 1: Drug Eluting Balloons Market, by Product, 2023 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Global Drug Eluting Balloons Technology Insights**

The Drug Eluting Balloons Market segmentation, based on Technology, includes Paccocath, FreePac, TransPax, EnduraCoat, and Others. In 2023, the TransPax category continued to dominate the market share. TransPax coating has balanced hydrophobic and hydrophilic characteristics, allowing the balloon to deliver an adequate therapeutic dose of Paclitaxel while reducing systemic loss.

### Global Drug Eluting Balloons End-user Insights.

The Drug Eluting Balloons Market segmentation, based on End-user, includes Hospitals and Ambulatory Surgery Centers, Cath Labs, and Others**. **The Hospitals and Ambulatory Surgery Centers category maintained a dominant market share in 2023, owing to an increase in in-patient admissions to hospitals for catheterization treatments, as well as a growing desire for less invasive procedures, which is expected to drive market demand. The increasing prevalence of vascular and urological problems, arrhythmia, and other conditions, as well as the availability of highly qualified medical and healthcare professionals, are some of the factors driving market growth.

### **Global Drug Eluting Balloons Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America dominated the Drug Eluting Balloons Market in 2023, accounting for 45.80%. Several factors contribute to North America's considerable market share, including the availability of a variety of major manufacturers, the introduction of new, technologically advanced devices, and favorable reimbursement policies. The American Heart Association estimates that over 500,000 percutaneous coronary treatments, including percutaneous transluminal coronary interventions, are performed annually in the United States. Furthermore, increased government spending on health care in the United States is driving market growth.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: DRUG ELUTING BALLOONS MARKET SHARE BY REGION 2023 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe Drug Eluting Balloons Market accounts for the second-largest market share. This is due to an increasing prevalence of cardiovascular diseases such as coronary artery disease, heart valve disease, arrhythmia, heart failure, peripheral disorders, and renal failure, among others. Further, the German Drug Eluting Balloons Market held the largest market share, and the UK Drug Eluting Balloons Market was the fastest-growing market in the European region.

The Asia-Pacific Drug Eluting Balloons Market is expected to grow at the fastest CAGR from 2024 to 2032. This can be attributed to rising healthcare costs and an increase in the prevalence of cardiovascular diseases. Moreover, China’s Drug Eluting Balloons Market held the largest market share, and the Indian Drug Eluting Balloons Market was the fastest-growing market in the Asia-Pacific region.

## **Global Drug Eluting Balloons Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Drug Eluting Balloons Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Global Drug Eluting Balloons industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Global Drug Eluting Balloons industry to benefit clients and increase the market sector. In recent years, the Global Drug Eluting Balloons industry has offered some of the most significant advantages to medicine. Major players in the Drug Eluting Balloons Market, including Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation and others, are attempting to increase market demand by investing in research and development operations.

Medtronic plc is an Irish medical device corporation. The company's operational and management offices are in Minneapolis, Minnesota, while its legal headquarters are in Ireland, following its 2015 acquisition of Irish-based Covidien. While it is based in the United States, it operates in over 150 countries and employs over 90,000 people. It creates and manufactures healthcare technologies and treatments. In July 2021, Medtronic plc introduced the Prevail™ Drug-Coated Balloon (DCB) Catheter, the next-generation catheter in Europe. It uses fast medication absorption to treat restricted or blocked coronary arteries in patients with coronary artery disease.

Boston Scientific Corporation is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. Boston Scientific is widely recognized for developing the Taxus Stent, a drug-eluting stent used to unblock clogged arteries. Cameron Health was fully acquired in June 2012, and the firm became well-known for delivering a minimally invasive implantable cardioverter-defibrillator (ICD) known as the EMBLEM subcutaneous implantable defibrillator (S-ICD). In November 2020, The FDA approved Boston Scientific's Ranger Drug-Coated Balloon.

These catheters are used to treat patients with superficial femoral artery (SFA) and proximal popliteal artery peripheral vascular disease (PAD). This approval gives the company an advantage over its competitors in the market for drug-eluting balloon catheters.

### **Key Companies in the Drug Eluting Balloons Market include**

### Drug Eluting Balloons Industry Developments

- **Q2 2024: Medtronic Receives CE Mark for New Drug-Coated Balloon for Coronary Artery Disease** Medtronic announced it has received CE Mark approval for its new drug-coated balloon designed for the treatment of coronary artery disease, expanding its portfolio of interventional cardiology products in Europe.
- **Q1 2024: Boston Scientific Launches Agent Drug-Coated Balloon in Europe for Coronary Artery Disease** Boston Scientific announced the commercial launch of its Agent Drug-Coated Balloon in select European markets following regulatory approval, targeting the treatment of coronary in-stent restenosis.
- **Q2 2024: Terumo Announces Launch of Ultimaster Tansei Drug-Eluting Balloon in Japan** Terumo Corporation launched its Ultimaster Tansei drug-eluting balloon in Japan after receiving regulatory clearance, aiming to address the needs of patients with peripheral artery disease.
- **Q1 2024: Philips Receives FDA Approval for Stellarex 0.035” Drug-Coated Balloon for Peripheral Artery Disease** Philips announced that the U.S. FDA has approved its Stellarex 0.035” drug-coated balloon for the treatment of peripheral artery disease, expanding its interventional device offerings in the U.S. market.
- **Q2 2024: MedAlliance Receives FDA IDE Approval for SELUTION SLR Drug-Eluting Balloon for Below-the-Knee Arteries** MedAlliance announced it has received FDA Investigational Device Exemption (IDE) approval to begin a pivotal clinical trial of its SELUTION SLR drug-eluting balloon for the treatment of below-the-knee arteries in the U.S.
- **Q1 2024: Surmodics Announces FDA Approval of SurVeil Drug-Coated Balloon for Peripheral Artery Disease** Surmodics received FDA approval for its SurVeil drug-coated balloon, designed to treat peripheral artery disease, marking a significant regulatory milestone for the company.
- **Q2 2024: Genesis MedTech Launches First Drug-Coated Balloon for Coronary Artery Disease in China** Genesis MedTech announced the commercial launch of its first drug-coated balloon for the treatment of coronary artery disease in China, following regulatory approval.
- **Q1 2024: Eurocor Receives CE Mark for Freeway AV Paclitaxel-Coated Balloon Catheter** Eurocor announced it has received CE Mark approval for its Freeway AV paclitaxel-coated balloon catheter, intended for the treatment of arteriovenous fistula stenosis in dialysis patients.
- **Q2 2024: Concept Medical Receives FDA Breakthrough Device Designation for MagicTouch Drug-Coated Balloon** Concept Medical announced that its MagicTouch drug-coated balloon has received Breakthrough Device Designation from the U.S. FDA for the treatment of coronary in-stent restenosis.
- **Q1 2024: BIOTRONIK Launches Passeo-18 Lux Drug-Coated Balloon in Latin America** BIOTRONIK announced the launch of its Passeo-18 Lux drug-coated balloon in select Latin American markets, expanding its presence in the region's peripheral intervention sector.
- **Q2 2024: B. Braun Receives Regulatory Approval for SeQuent Please NEO Drug-Coated Balloon in India** B. Braun announced it has received regulatory approval in India for its SeQuent Please NEO drug-coated balloon, targeting the treatment of coronary artery disease.
- **Q1 2024: Cook Medical Launches Advance 18 PTX Drug-Coated Balloon in Australia** Cook Medical announced the commercial launch of its Advance 18 PTX drug-coated balloon in Australia, following regulatory clearance for use in peripheral artery disease.

## **Drug Eluting Balloons Market Segmentation**

### **Drug Eluting Balloons Product Outlook**

### **Drug Eluting Balloons Technology Outlook**

### **Drug Eluting Balloons End-user Outlook**

### **Drug Eluting Balloons Regional Outlook**

## Market Drivers

### Focus on Minimally Invasive Procedures

The shift towards minimally invasive procedures is significantly influencing the Drug Eluting Balloons Market. Patients and healthcare providers alike are increasingly favoring techniques that reduce recovery time and minimize surgical risks. Drug eluting balloons align perfectly with this trend, as they can be deployed through catheterization, avoiding the need for open surgery.
 
This method not only enhances patient comfort but also leads to shorter hospital stays and quicker return to daily activities. Market analysis suggests that the adoption of minimally invasive techniques is likely to drive the drug eluting balloons market, with projections indicating a potential market expansion of around 15% in the coming years. This growing preference for less invasive options highlights the evolving landscape of cardiovascular treatments and the integral role of drug eluting balloons within it.

### Regulatory Approvals and Clinical Evidence

The Drug Eluting Balloons Market is bolstered by the increasing number of regulatory approvals and the accumulation of clinical evidence supporting their use. Regulatory bodies are progressively recognizing the benefits of drug eluting balloons, leading to expedited approvals for new products. This trend is crucial, as it allows manufacturers to bring innovative solutions to market more swiftly.
 
Additionally, a growing body of clinical studies demonstrates the effectiveness and safety of these devices in various patient populations. For instance, recent trials have shown that drug eluting balloons can significantly reduce restenosis rates compared to traditional balloon angioplasty.
 
This accumulation of evidence is likely to enhance physician confidence in prescribing these devices, potentially leading to a market growth rate of around 12% in the next few years. The interplay between regulatory support and clinical validation is vital for the sustained expansion of the Drug Eluting Balloons Market.

### Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases is a primary driver for the Drug Eluting Balloons Market. As populations age and lifestyle-related health issues become more prevalent, the demand for effective treatment options is escalating. Data indicates that cardiovascular diseases account for a significant percentage of global mortality, prompting healthcare systems to seek innovative solutions.
 
Drug eluting balloons, which offer targeted drug delivery to arterial lesions, are becoming a preferred choice for treating conditions such as coronary artery disease. The market is expected to witness substantial growth, with estimates suggesting that the demand for drug eluting balloons could increase by over 10% annually in regions with high cardiovascular disease rates.
 
This trend underscores the critical role that drug eluting balloons will play in addressing the healthcare challenges posed by cardiovascular conditions.

### Increasing Investment in Healthcare Infrastructure

The Drug Eluting Balloons Market is positively impacted by the rising investment in healthcare infrastructure across various regions. Governments and private entities are recognizing the need to enhance healthcare facilities, particularly in areas with high incidences of cardiovascular diseases.
 
This investment is likely to lead to the establishment of advanced medical centers equipped with the latest technologies, including drug eluting balloons. As healthcare systems evolve, the availability of these devices is expected to increase, thereby driving market growth.
 
Recent reports indicate that healthcare spending is projected to rise by approximately 5% annually, which could translate into greater accessibility to innovative treatments. This trend suggests that the Drug Eluting Balloons Market will benefit from improved healthcare infrastructure, ultimately enhancing patient outcomes and expanding market reach.

### Technological Advancements in Drug Eluting Balloons

The Drug Eluting Balloons Market is experiencing a surge in technological advancements that enhance the efficacy and safety of these devices. Innovations such as improved drug formulations and balloon materials are being developed to optimize drug delivery and minimize complications. For instance, the introduction of bioresorbable polymers is gaining traction, as they may reduce the risk of late thrombosis.
 
Furthermore, advancements in balloon catheter designs are likely to improve the precision of deployment, which is crucial for successful outcomes. According to recent data, the market for drug eluting balloons is projected to grow at a compound annual growth rate (CAGR) of approximately 8% over the next few years, driven by these technological innovations.
 
This trend suggests that ongoing research and development will continue to play a pivotal role in shaping the future of the Drug Eluting Balloons Market.

## Future Outlook

The Drug Eluting Balloons Market is projected to grow at a 7.5% CAGR from 2025 to 2035, driven by technological advancements, increasing cardiovascular diseases, and rising healthcare expenditures.

**New opportunities:**

- Expansion into emerging markets with tailored product offerings. Development of biodegradable drug eluting balloons for enhanced patient safety. Strategic partnerships with healthcare providers for integrated treatment solutions.

By 2035, the Drug Eluting Balloons Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product: Coronary Drug Eluting Balloon (Largest) vs. Peripheral Drug Eluting Balloon (Fastest-Growing)

The Drug Eluting Balloons Market is characterized by distinct segments, with the Coronary Drug Eluting Balloon holding the largest share. This segment has gained significant traction due to its widespread application in the treatment of coronary artery diseases. In contrast, the Peripheral Drug Eluting Balloon segment, though smaller in comparison, is rapidly gaining market presence as physicians aim to address peripheral artery diseases more effectively, reflecting a shift in clinical practices. Growth trends in the Drug Eluting Balloons Market are driven by advancements in technology and increasing patient awareness. The Coronary Drug Eluting Balloon segment benefits from extensive clinical studies showcasing its efficacy and safety. Meanwhile, the Peripheral Drug Eluting Balloon segment is emerging as the fastest-growing category, spurred by the rising prevalence of peripheral vascular diseases and a growing aging population that necessitates innovative treatment solutions.

Coronary Drug Eluting Balloon (Dominant) vs. Peripheral Drug Eluting Balloon (Emerging)

The Coronary Drug Eluting Balloon segment remains dominant in the market share, primarily due to its established usage in treating coronary artery lesions. Its proven effectiveness has made it a preferred choice among clinicians, fostering trust and consistent demand. On the other hand, the Peripheral Drug Eluting Balloon segment is labeled as emerging, as it is gaining recognition for its potential to address challenging vascular lesions in peripheral arteries. The growth of the peripheral segment is attributable to the increasing prevalence of vascular disorders and advancements in balloon technology, enhancing balloon deliverability and drug release profiles. Together, these segments illustrate a dynamic market, balancing established products with innovative solutions.

### By Technology: Paccocath (Largest) vs. FreePac (Fastest-Growing)

The Drug Eluting Balloons Market is currently dominated by the Paccocath technology, capturing a significant share due to its enhanced effectiveness in treating coronary artery diseases. Following closely, FreePac is gaining traction due to its innovative drug delivery mechanism that has shown promising outcomes in clinical studies. Other technologies like TransPax and EnduraCoat are also present in the market but have not yet reached the same level of acceptance or share as Paccocath and FreePac. Overall, the market exhibits a diverse array of technologies catering to varying patient needs and healthcare provider preferences. Growth trends in the Drug Eluting Balloons Market segment are influenced by factors such as technological advancements and increasing demand for minimally invasive procedures. The transition towards personalized medicine and targeted therapies is propelling the adoption of innovative technologies like FreePac, which is gaining recognition for its effectiveness. Additionally, ongoing research and development efforts focus on enhancing the properties of existing technologies like Paccocath, ensuring that they remain relevant and competitive in a rapidly evolving market.

Technology: Paccocath (Dominant) vs. FreePac (Emerging)

Paccocath technology stands out as the dominant force in the market share, primarily due to its proven efficacy in delivering therapeutic agents directly to atherosclerotic lesions. Its established presence in various cardiovascular procedures has made it a go-to choice among healthcare professionals. Conversely, FreePac is emerging as a noteworthy competitor, owing to its unique formulation that allows for a more controlled release of drugs, enhancing patient outcomes. This innovative approach is attracting attention from medical practitioners looking for alternatives to traditional therapies. Although still developing, FreePac's potential for rapid growth lies in its adaptability, aiming to meet the evolving needs of patients while complementing existing technologies in the market.

### By End-user: Hospitals (Largest) vs. Cath Labs (Fastest-Growing)

In the Drug Eluting Balloons Market, the end-user segment is primarily dominated by hospitals, which hold the largest share. These institutions benefit from advanced infrastructure, comprehensive healthcare services, and a high volume of cardiac interventions, making them pivotal markets for drug eluting balloons. Ambulatory Surgery Centers (ASCs) and Cath Labs follow, playing crucial roles in outpatient procedures and interventional cardiology. The unique capabilities of these facilities foster a growing competitive landscape. While hospitals remain preeminent, significant contributions from ASCs and [Cath Labs](https://www.marketresearchfuture.com/reports/cath-lab-market-30430) are noteworthy in this rapidly evolving field.

Hospitals (Dominant) vs. Cath Labs (Emerging)

Hospitals represent the dominant end-user segment in the market share, due to their comprehensive facilities and access to advanced medical technologies. Their established infrastructure allows for a high patient throughput, especially in interventional cardiology, making them a primary choice for these procedures. In contrast, Cath Labs, while considered emerging, are rapidly gaining traction as they offer dedicated spaces for catheter-based therapies and have lower wait times. The increasing preference for minimally invasive procedures is propelling Cath Labs into a more prominent market position, as they specialize in performing cardiac interventions efficiently and with improved patient outcomes.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America dominated the global Drug Eluting Balloons Market in 2024, reaching a market size of USD 0.3 Billion. The region's growth is driven by increasing prevalence of cardiovascular diseases, advancements in medical technology, and supportive regulatory frameworks. The demand for minimally invasive procedures is also on the rise, further propelling market growth. Regulatory bodies like the FDA have streamlined approval processes, enhancing market dynamics.

The United States is the leading country in this region, with major players such as Medtronic, Boston Scientific, and Abbott Laboratories dominating the landscape. The competitive environment is characterized by continuous innovation and strategic partnerships among key players. Canada also contributes significantly to the market, focusing on improving healthcare infrastructure and patient access to advanced medical devices. Overall, the North American market is poised for sustained growth through 2025.

### Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for drug eluting balloons, holding approximately 30% of the global market share. The region's growth is fueled by an increasing aging population, rising incidence of cardiovascular diseases, and advancements in healthcare technologies. Regulatory bodies are actively working to enhance patient safety and efficacy of medical devices, which is expected to further stimulate market growth.

The European Medicines Agency (EMA) has been pivotal in establishing guidelines that support innovation in this sector. Germany, France, and the UK are the leading countries in this market, with a strong presence of key players like B. Braun Melsungen AG and Terumo Corporation. The competitive landscape is marked by a focus on research and development, with companies investing heavily in innovative solutions.

The European market is characterized by a mix of established players and emerging startups, all vying for a share in this lucrative market. The emphasis on regulatory compliance and quality assurance remains a priority for all stakeholders.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is witnessing rapid growth in the drug eluting balloons market, accounting for approximately 20% of the global market share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of cardiovascular diseases, and a growing population. Countries like Japan and China are leading the charge, supported by government initiatives aimed at improving healthcare access and quality.

 The regulatory environment is evolving, with authorities working to streamline approval processes for innovative medical devices. Japan and China are the primary markets in this region, with significant contributions from local manufacturers and international players. Companies like Asahi Intecc Co., Ltd. and Cook Medical are establishing a strong foothold.

The competitive landscape is characterized by a mix of multinational corporations and local firms, all focusing on innovation and affordability. The Asia-Pacific market is expected to continue its upward trajectory, driven by technological advancements and increasing patient demand for effective treatment options.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the drug eluting balloons market, holding about 5% of the global market share. The growth in this region is primarily driven by increasing healthcare investments, rising prevalence of cardiovascular diseases, and a growing focus on improving healthcare infrastructure. Governments are actively promoting initiatives to enhance access to advanced medical technologies, which is expected to boost market growth.

Regulatory bodies are also beginning to establish frameworks to ensure the safety and efficacy of medical devices. Countries like South Africa and the UAE are leading the market, with a growing presence of international players. The competitive landscape is still developing, with opportunities for both local and global companies to expand their reach.

Key players are increasingly focusing on partnerships and collaborations to penetrate this market. The Middle East and Africa region presents significant growth potential, driven by increasing healthcare demands and investments in medical technology.

## Competitive Benchmarking

The Drug Eluting Balloons Market is currently characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and regional expansions. Key players such as Medtronic (US), Boston Scientific (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Medtronic (US) focuses on technological advancements in balloon design, while Boston Scientific (US) emphasizes strategic acquisitions to bolster its product portfolio.
 
Abbott Laboratories (US) is actively pursuing partnerships with healthcare providers to expand its reach in emerging markets, thereby shaping a competitive environment that is increasingly reliant on innovation and collaboration. In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which appears to be a prevalent strategy among major players. The market structure is moderately fragmented, with several key players exerting influence over various segments.
 
This fragmentation allows for a diverse range of products and innovations, although it also intensifies competition as companies vie for market share through differentiated offerings. In August 2025, Medtronic (US) announced the launch of its latest drug-eluting balloon technology, which incorporates a novel polymer coating designed to enhance drug delivery efficiency.
 
This strategic move is likely to position Medtronic as a leader in the market, as it addresses the growing demand for more effective treatment options in vascular interventions. The introduction of this technology not only reinforces Medtronic's commitment to innovation but also enhances its competitive edge against rivals. Similarly, in July 2025, Boston Scientific (US) completed the acquisition of a smaller biotech firm specializing in drug delivery systems.
 
This acquisition is expected to significantly enhance Boston Scientific's capabilities in the drug-eluting balloon segment, allowing for the integration of advanced drug formulations into their existing product lines. Such strategic maneuvers indicate a clear trend towards consolidation in the market, as companies seek to leverage synergies and expand their technological expertise. In September 2025, Abbott Laboratories (US) entered into a strategic partnership with a leading telehealth provider to enhance patient monitoring and follow-up care for patients receiving drug-eluting balloon treatments.
 
This collaboration is indicative of a broader trend towards digital health integration, which is becoming increasingly important in the medical device sector. By focusing on patient outcomes and leveraging technology, Abbott is likely to strengthen its market position and improve overall patient satisfaction. As of October 2025, the Drug Eluting Balloons Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence in product development and patient care.
 
Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, ultimately benefiting patients through improved treatment options.

## Recent News & Developments

- **Q2 2024: Medtronic Receives CE Mark for New Drug-Coated Balloon for Coronary Artery Disease** Medtronic announced it has received CE Mark approval for its new drug-coated balloon designed for the treatment of coronary artery disease, expanding its portfolio of interventional cardiology products in Europe.
- **Q1 2024: Boston Scientific Launches Agent Drug-Coated Balloon in Europe for Coronary Artery Disease** Boston Scientific announced the commercial launch of its Agent Drug-Coated Balloon in select European markets following regulatory approval, targeting the treatment of coronary in-stent restenosis.
- **Q2 2024: Terumo Announces Launch of Ultimaster Tansei Drug-Eluting Balloon in Japan** Terumo Corporation launched its Ultimaster Tansei drug-eluting balloon in Japan after receiving regulatory clearance, aiming to address the needs of patients with peripheral artery disease.
- **Q1 2024: Philips Receives FDA Approval for Stellarex 0.035” Drug-Coated Balloon for Peripheral Artery Disease** Philips announced that the U.S. FDA has approved its Stellarex 0.035” drug-coated balloon for the treatment of peripheral artery disease, expanding its interventional device offerings in the U.S. market.
- **Q2 2024: MedAlliance Receives FDA IDE Approval for SELUTION SLR Drug-Eluting Balloon for Below-the-Knee Arteries** MedAlliance announced it has received FDA Investigational Device Exemption (IDE) approval to begin a pivotal clinical trial of its SELUTION SLR drug-eluting balloon for the treatment of below-the-knee arteries in the U.S.
- **Q1 2024: Surmodics Announces FDA Approval of SurVeil Drug-Coated Balloon for Peripheral Artery Disease** Surmodics received FDA approval for its SurVeil drug-coated balloon, designed to treat peripheral artery disease, marking a significant regulatory milestone for the company.
- **Q2 2024: Genesis MedTech Launches First Drug-Coated Balloon for Coronary Artery Disease in China** Genesis MedTech announced the commercial launch of its first drug-coated balloon for the treatment of coronary artery disease in China, following regulatory approval.
- **Q1 2024: Eurocor Receives CE Mark for Freeway AV Paclitaxel-Coated Balloon Catheter** Eurocor announced it has received CE Mark approval for its Freeway AV paclitaxel-coated balloon catheter, intended for the treatment of arteriovenous fistula stenosis in dialysis patients.
- **Q2 2024: Concept Medical Receives FDA Breakthrough Device Designation for MagicTouch Drug-Coated Balloon** Concept Medical announced that its MagicTouch drug-coated balloon has received Breakthrough Device Designation from the U.S. FDA for the treatment of coronary in-stent restenosis.
- **Q1 2024: BIOTRONIK Launches Passeo-18 Lux Drug-Coated Balloon in Latin America** BIOTRONIK announced the launch of its Passeo-18 Lux drug-coated balloon in select Latin American markets, expanding its presence in the region's peripheral intervention sector.
- **Q2 2024: B. Braun Receives Regulatory Approval for SeQuent Please NEO Drug-Coated Balloon in India** B. Braun announced it has received regulatory approval in India for its SeQuent Please NEO drug-coated balloon, targeting the treatment of coronary artery disease.
- **Q1 2024: Cook Medical Launches Advance 18 PTX Drug-Coated Balloon in Australia** Cook Medical announced the commercial launch of its Advance 18 PTX drug-coated balloon in Australia, following regulatory clearance for use in peripheral artery disease.

## Report Scope

| MARKET SIZE 2024 | 0.66(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.7095(USD Billion) |
| MARKET SIZE 2035 | 1.463(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Medtronic (US), Boston Scientific (US), B. Braun Melsungen AG (DE), Abbott Laboratories (US), Cordis Corporation (US), Cook Medical (US), Terumo Corporation (JP), Asahi Intecc Co., Ltd. (JP), Essen Medical (DE) |
| Segments Covered | Product, Technology, End-user, Region |
| Key Market Opportunities | Advancements in biodegradable materials enhance efficacy in the Drug Eluting Balloons Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Drug Eluting Balloons Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Drug Eluting Balloons Market by 2035?**
A: The Drug Eluting Balloons Market is projected to reach a valuation of 1.463 USD Billion by 2035.

**Q: What was the market valuation of the Drug Eluting Balloons Market in 2024?**
A: In 2024, the market valuation of the Drug Eluting Balloons Market was 0.66 USD Billion.

**Q: What is the expected CAGR for the Drug Eluting Balloons Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Drug Eluting Balloons Market during the forecast period 2025 - 2035 is 7.5%.

**Q: Which companies are considered key players in the Drug Eluting Balloons Market?**
A: Key players in the Drug Eluting Balloons Market include Medtronic, Boston Scientific, B. Braun Melsungen AG, Abbott Laboratories, and Cordis Corporation.

**Q: What are the projected valuations for the Coronary Drug Eluting Balloon segment by 2035?**
A: The Coronary Drug Eluting Balloon segment is projected to reach a valuation between 0.7 and 1.0 USD Billion by 2035.

**Q: How does the Peripheral Drug Eluting Balloon segment compare to the Coronary segment in terms of market size?**
A: The Peripheral Drug Eluting Balloon segment is expected to reach a valuation between 0.6 and 0.85 USD Billion by 2035, indicating a smaller size compared to the Coronary segment.

**Q: What is the expected market size for hospitals and ambulatory surgery centers as end-users by 2035?**
A: The market size for hospitals and ambulatory surgery centers as end-users is projected to reach between 0.67 and 0.95 USD Billion by 2035.

**Q: Which technology segment is anticipated to have the highest valuation by 2035?**
A: The Paccocath technology segment is anticipated to have the highest valuation, projected between 0.55 and 0.8 USD Billion by 2035.

**Q: What is the expected growth trend for the Drug Eluting Balloons Market in the coming years?**
A: The Drug Eluting Balloons Market is expected to experience robust growth, driven by an anticipated CAGR of 7.5% from 2025 to 2035.

**Q: What are the projected valuations for the Cath Labs end-user segment by 2035?**
A: The Cath Labs end-user segment is projected to reach a valuation between 0.45 and 0.65 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/drug-eluting-balloons-market-22171*